Objective:
W hen colorectal cancer (CRCa) is diagnosed at its earliest stage, more than 9 in 10 people with CRCa will survive their disease for 5 years or more, compared with less than 1 in 10 when diagnosed at the latest disease stage. 1 The utilization of bowel symptoms as the primary diagnostic basis for CRCa has been shown to have a very poor positive predictive value. 2 Risk of CRCa in symptomatic patients can be assessed by different investigations. Lower gastrointestinal (LGI) endoscopy is the gold standard investigation, but the large scale of its application has resource implications and its cost-effectiveness depends on the predictive values of different symptoms. Guaiac fecal occult blood test has good sensitivity of 87% to 98% in CRCa detection, but highly variable and often unsatisfactory specificity (13% to 79%), requiring the repetition of the test on multiple stool samples. To date, the fecal occult blood test is neither recommended nor available for use as an intermediate test. [3] [4] [5] [6] The fecal immunochemical testing requires a single stool sampling. Four systems are fully automated, and provide a quantitative measure of hemoglobin, allowing selection of a threshold of positivity to fit specific circumstances. As a result, the research data available on sensitivity and specificity for CRCa are based on small numbers of cancers. The data suggest that, depending on the selected threshold for positivity, the sensitivity for CRCa varies between 35% and 86% with specificity between 85% and 95%. 5, 6 However, there are no data on the sensitivity of the newer quantitative test for early-stage cancers. The multi-target stool DNA test, when compared with the fecal immunochemical test in a large multicenter study, the test showed a better specificity (92% vs 73%), but a lower sensitivity (90% vs 96%). 7 An alternative approach for fecal-based tests is exhaled breath testing with the potential for high compliance because of the nature of the test and the possibility for testing more than one disease with different VOC discriminative signatures. 8, 9 Researchers using gas chromatography mass spectrometry (GC-MS) have suggested the existence of a breath volatile organic compounds (VOCs) profile specific to CRCa. 10 GC-MS is good technique for VOC identification, however, is semi-quantitative in nature, and thus limited in the ability of research findings to be reproduced by different research groups. Furthermore, there is a substantial analytical time for each sample, which does not naturally lend itself to high throughput analysis. Selected ion flow tube mass spectrometry (SIFT-MS) has the advantage of being quantitative and permits real-time analysis. 11, 12 There has only been one previous study evaluating the breath profile of patients following curative surgical resection of CRCa. 13 That study utilized GC-MS and suggested that following removal of the CRCa that there was a change in the exhaled breath VOC profile, further highlighting a potential association between tumor metabolism and VOC production. The authors also hypothesized that these results may provide a rationale for using breath analysis in the follow-up of patients after surgery and monitoring of disease-free survival. 13 However, that study did not examine patients with evidence of CRCa recurrence. None of the previous studies have externally validated the initial discovery findings. In our investigations, we addressed some of the challenges in cancer volatile biomarker studies by (1) using a quantitative method to determine test threshold and (2) externally validating the finding of our biomarker profiling study in 2 patient cohorts.
The objectives of this study using, SIFT-MS were to
(1) Identify changes in VOC concentration in exhaled breath of patients with CRCa compared with those with other colorectal diseases or normal LGI tract (control) from a prospective cohort study; (2) Validate these findings in a further prospectively collected cohort of patients with colorectal symptoms or disease; (3) Identify changes in VOCs from exhaled breath observed with the presence of recurrence following CRCa surgical resection. 
METHODS

Inclusion Criteria
The inclusion criteria included patients attending St Mary's Hospital for LGI endoscopy or surgery for CRCa or investigation of LGI symptoms [studies (i) and (ii)]. Patients attending oncological clinic for follow-up were recruited for study (iii).
Exclusion Criteria
The exclusion criteria included control and cancer patients with a documented active infection or liver disease, as both are known to effect VOC production and metabolism.
Breath Sampling Methodology
All patients were asked to sign a consent form to be included in this study. We followed the sampling protocol used in our previous clinical studies 9 that was informed by our investigations on the influence of breath maneuvers and hospital environment on VOC measurement. 14, 15 Patients were fasted for a minimum of 4 hours before their breath sample collection. Patients were rested in the same area for at least 20 minutes before breath sampling and all breath samples were retrieved before endoscopy or surgery. Patients were asked to perform a single deep nasal inhalation followed by complete exhalation via their mouth into secure double thickness (2 Â 25 mm) Nalophan (Kalle UK Ltd., Witham, UK) bags via a 1 mL Luer lok syringe (Terumo Europe, Leuven, Belgium).
Sample Analysis
For each VOC measurement, the syringe plunger was removed from the 1 mL Luer lok syringe and the Nalophan bag was directly connected via the syringe barrel to the sample inlet arm of the SIFT-MS instrument. For the multi-ion monitoring mode, selective VOCs from breath were analyzed for a total of 60 seconds and measured concentrations were averaged over this time for each VOC. As this was a single-center study, each breath sample was analyzed within 1 hour of the sample being taken from the patient, and therefore, Nalophan breath bags were used as in previous research conducted by our group. 9 Our methodological studies demonstrated the stability of trace VOCs up to 2 hours from the time of patient sampling. 16 Furthermore, ambient room air was sampled at the time of patient sampling to ensure that this was not a confounding factor in the results presented. 16 
Selected Ion Flow-tube Mass Spectrometry (SIFT-MS)
SIFT-MS permits online, real-time VOC quantification.
11,12
The principle of SIFT-MS is based upon direct mass spectrometric analysis by chemical ionization of the VOCs in air or vapor samples.
Selected precursor ions (H 3 O
þ , NO þ , and O 2 þ ) are injected into the helium carrier gas, and ionize the VOCs within the breath samples, with the generation of characteristic product ions, which are detected by the quadrupole mass spectrometer downstream. By measuring the count rate of both precursor ions and the characteristic product ions at the downstream detection system, a real-time quantification is achieved, realizing the absolute concentration of trace and volatile compounds at the parts-per-billion by volume or parts-per-million by volume. SIFT-MS has been utilized in the study of VOCs in breath and urine from patients with conditions including cystic fibrosis and bladder cancer. 17, 18 The SIFT-MS technique allows real-time detection and quantification of VOCs within biological samples such as exhaled breath without sample preparation. 19 We have previously confirmed the reproducibility of VOCs measurements using SIFT-MS. 20 Twenty-nine VOCs were investigated using SIFT-MS following our previously published study protocols 9 (Appendix A).
Clinical Data
A detailed medical proforma was completed by the consenting medical practitioner or research fellow using information provided by the patient as well as clinical investigations. These data included patient demographics, tumor characteristics, comorbidities, medications, and lifestyle measures. Diagnostic endoscopy and/or operative findings were recorded for each patient.
Criterion Standard for Comparison
Endoscopy findings confirmed with histological examination were used as the gold standard for patient classification into the CRCa or control cohorts. For postoperative patients, the latest CT
Statistical Analysis
SIFT-MS output data provide measured concentration of VOCs from exhaled breath. These concentrations were then compared using univariate statistics, Kruskal-Wallis test, across the study groups. VOCs that were significant in univariate statistics were then taken forward into a multivariable logistic regression model with the dependent variable being the presence of CRCa. To construct the receiver operating characteristic (ROC) curves, cancer status was used as the dependent variable and the sum concentrations of significant VOCs from the multivariable logistic regression model were used as the independent variables. P value of < 0.05 was used to assign statistical significance. All statistical analyses were performed using the statistical software SPSS (version 22) (Statistical Package for the Social Sciences software, Version 22, SPSS Chicago, IL).
Cross-Platform GC-MS Validation
In order to confirm the identity of VOCs obtained in the exhaled breath using SIFT-MS, we conducted cross-platform validation with GC-MS being the standard separation technique. Exhaled breath was collected using the same methodology from 20 patients. The VOC content from each Nalophan breath bag was transferred using a SKC 210-1002 Series air-sampling pocket pump (PA) (210-1002MTX, SKC ltd., Dorset, UK). at 50 mL/min onto an inert coated stainless steel Tenax/Carbograph-5TD sorbent tubes (Markes International Ltd, Llantrisant, UK) before GC-MS analysis. An Agilent 7890B GC with 5977A MSD (Agilent Technologies, Cheshire, UK), coupling to a Markes TD-100 thermal desorption unit (TDU) was used. A 2-stage thermal desorption program was used at 50 mL/min constant helium flow rate. In the primary desorption stage, the TD tube sample was dry-purged for 3 minutes before being heated to 2808C for 10 minutes. During secondary desorption stage, VOC from the cold trap (U-T12ME-2S) was rapidly desorbed from 108C to 2908C at 99 8C/min heating rate and held for 4 minutes to completely transfer the VOCs onto GC. Flow path from TDU to GC was heated constantly at 1408C.
VOCs separation was performed on a ZB-624 capillary column (60 m Â 0.25 mm ID Â 1.40 mm d f ; Phenomenex Inc, Torrance) programmed at 1.0 mL/min helium carrier. Oven temperature profile was set at 408C initially for 4 minutes, ramp to 1008C (5 8C/min with 1 minute hold), ramp to 1108C (5 8C/min with 1 minute hold), ramp to 2008C (5 8C/min with 1 minute hold), final ramp to 2408C at 10 8C/min with 4 minutes hold. The MS transfer line was maintained at 2408C, while the EI source was set at 70 eV and 2308C. MS analyzer was set to acquire over the range of 20 to 250 m/z with data acquisition approximated to 6 scan/s. The GC-MS data were processed using MassHunter software version B.07 SP1 (Agilent Technologies), while MS data of the separated VOC component is compared with NIST Mass Spectral Library (National Institute of Standards and Technology version 2.0) for identification.
RESULTS
Study (i): Profiling Diagnostic Investigation
This study included 150 patients [50 patients with CRCa, 50 patients with other conditions of the LGI tract (positive controls), and 50 patients with a normal LGI tract (negative controls)]. Of the positive control patients, 15 (30%) had inflammatory bowel disease, 21 (42%) had polyps (14 hyperplastic and 7 tubular adenomas) within the LGI tract, and 14 (28%) had diverticular disease. All patients with diverticular disease and inflammatory bowel disease did not have active diverticulitis or colitis at the time of breath sampling.
Comparative analysis of patient medical comorbidities revealed no significant differences between the groups with the exception of an increase in the proportion of patients aged 70 years or older in the CRCa group (Table 1) . There was also an increased proportion of patients receiving bowel preparation in the control groups (Table 1) . Comparative analysis of presenting symptoms that stimulated referral for LGI endoscopy showed no significant differences between the groups with the exception of an increased proportion of patients with anemia in the CRCa group (Table 1) . Comparative analysis of utilization of medication between the groups showed an increase use of proton pump inhibitor [37% (CRCa) vs 10% (positive control) vs 24% (negative control); P ¼ 0.01) and clopidogrel (7% (CRCa) vs 0% (positive control) vs 0% (negative control); P ¼ 0.04] within the CRCa group. Of the 50 patients with CRCa, 52% were tumors of the rectum, 66% were moderately differentiated tumors, 48% T3 and 52% N0 tumors, and 34% of patients received neoadjuvant therapy preoperatively (Table 2) .
Seven compounds were found to be significantly different between cancer and control groups, of which only propanal (NOþ) was significantly associated with CRCa in multivariate analysis (Table 3) . In parallel to SIFT-MS analysis, cross-platform analysis by GC-MS unravels that the propanal peak was distinctly observed in the gas chromatogram at a retention time (RT) of 8.92 minutes among the cancer breath samples. The selected ZB-624 capillary column has provided sufficient resolution efficiency to separate propanal from the abundant acetone peak (RT of 9.11 minutes), although they both possesses the common fragment ion of 58 m/z. Appendix B dictates high similarity of the de-convoluted mass spectral details of propanal peak (character ions of 29, 39, and 58 m/z) with the NIST library matching. Propanal (NOþ) performed well as a single breath biomarker for CRCa when compared with negative controls [area under the ROC curve ¼ 0.90 AE 0.03 (Fig. 1A) ] and positive controls [area under the ROC curve ¼ 0.83 AE 0.04 (Fig. 1B) ]. In distinguishing CRCa from negative controls, propanal as a single breath biomarker based on a threshold of 28 ppbv had a sensitivity of 96% and a specificity of 76%. Propanal at a threshold of 28 ppbv was also able to distinguish CRCa from positive control patients with a sensitivity of 90% and a specificity of 66%.
To ensure that the elevated propanal concentration seen in the CRCa was not the result of a confounding factor that differed between the groups, multivariable linear regression analysis was performed and demonstrated that the presence of CRCa was the sole factor significantly associated with elevated levels of propanal (Appendix C). The utilization of bowel preparation did not significantly influence the level of propanal.
Study (ii): Independent Diagnostic Validation
In total, 79 patients were studied, 25 with CRCa and 54 control patients. Of the 54 control patients, 31 (57.4%) had a normal LGI tract on endoscopy, 12 (22%) had polyps, 7 (13%) had diverticular disease, and 4 (7%) had inflammatory bowel disease. Comparative analysis of patient medical comorbidities, use of medication, and presenting symptoms revealed no significant differences between the groups with the exception of an increase in the proportion of patients aged 70 years or older and increased presentation with anemia in the CRCa group.
Propanal was significantly elevated in the CRCa group when compared with the control group (median 30 vs 19 ppbv; P < 0.01). Propanal (NOþ) performed well as a single breath biomarker for CRCa when compared with control patients with an area under the ROC curve of 0.79 AE 0.06 (Fig. 2) . Again, using a threshold of 28 ppbv, this gave propanal a sensitivity of 83.3% and a specificity of 84.7% for the diagnosis of CRCa.
Study (iii): Clinical Validation With Tumor Recurrence
In total, 40 patients were studied, 19 postoperative patients with no evidence of recurrence, and 21 patients with documented recurrence. Of the patients with recurrence, 5 patients had isolated hepatic recurrence, and 16 patients had either peritoneal recurrence alone or hepatic and peritoneal recurrence simultaneously. Comparative analysis of patient medical comorbidities and use of medication revealed no significant differences between the groups.
Propanal concentration was significantly elevated in patients with CRCa recurrence compared with the nonrecurrence group (median 38 vs 19 ppbv; P < 0.01). Propanal (NOþ) was employed as a single breath biomarker in identifying postoperative patients with CRCa recurrence with an area under the ROC curve of 0.81 AE 0.07 (Fig. 3) . Using a threshold of 28 ppbv, this gave propanal a sensitivity of 71.4% and a specificity of 90.9% in identifying patients with recurrence following surgery. 
DISCUSSION
The results of this study suggest that propanal may have the potential to be a single breath biomarker for the diagnosis of CRCa. Propanal appeared to distinguish with a good diagnostic accuracy patients with CRCa from patients with other colorectal diseases and subjects with an endoscopically normal LGI tract. Those findings have been validated in an independent diagnostic study and in patients with CRCa recurrence. The elevation in propanal concentration was not influenced by patient factors or utilization of bowel preparation as shown in multivariate analysis (Appendix C). Propanal was not a component of previously generated and validated VOC breath model for oesophago-gastric cancer 9 suggesting that cancers of upper and LGI tract have distinct nonoverlapping breath profiles that may permit cancer-specific analysis in future clinical practice.
A previous study by Altomare et al 10 using GC-MS identified 15 VOCs from exhaled breath that significantly differed between CRCa and control patients. Of these nonanal and decanal were the only aldehydes detected. Altomare et al 10 did attempt to validate their findings in a prospective cohort of patients; however, the initial model that was developed in 78 patients was validated in only 25 patients. The methodology employed by Altomare et al 10 used underivitized analysis of aldehydes on GC-MS, which permits measurement of long-chain aldehydes such as nonanal and decanal, but not shorter aldehydes such as propanal, which are lost, as they are more volatile. This may be a major factor in the difference in results observed between our investigation and the study by Altomare et al. 10 Furthermore, a recent study by Amal et al, 21 similarly using GC-MS, did not identify aldehydes in exhaled breath that differed between CRCa and control groups. The different mass spectrometry techniques may account for the differences between studies. A combination of short and long chain aldehydes as the basis for the diagnostic model in CRCa needs further investigation.
Propanal (CH 3 CH 2 CHO) is a saturated 3-carbon aldehyde and is a structural isomer of acetone. Previous investigation has demonstrated reliable quantification of propanal aldehyde by SIFT-MS due to specific hydride transfer reaction that occurs between saturated aldehyde and NOþ reagent. 18 Cross-platform validation using gas chromatography mass-spectrometry confirmed propanal identity. The most plausible explanation for the elevation in propanal concentration is the derangement of aldehyde metabolism in CRCa. 22 Specifically, aldehyde dehydrogenase-1 expression has been demonstrated to be dysregulated in CRCa, and independently affect longterm survival, along with response to neoadjuvant chemotherapy. 23, 24 Another contributing factor to the elevation of propanal is the changes in the gut microbiota and the complex interplay between the microbiome and the adaptive immune response in cancer development. 25, 26 As an initial investigation toward the development of a breath test for CRCa, the advantages of our studies include (1) the discovery of a single volatile biomarker; (2) setting up a test threshold for diagnosis using quantitative mass spectrometry technique that does not require sample preparation; (3) the conduction of independent validation in 2 prospective cohorts of patients with CRCa and with tumor recurrence after resection; and (4) all patients had LGI endoscopy as the criterion standard for comparison. Using a threshold of 28 ppbv, it was possible to distinguish cancer from control groups with a diagnosis accuracy ranging from 79% to 90%, and is comparable with fecal occult blood and fecal immunochemical tests that are currently in clinical practice. [3] [4] [5] [6] Furthermore, it was possible to identify recurrent CRCa with a sensitivity and specificity of 71.4% and 90.9%, respectively, and compares well with the use of CEA, which has a sensitivity of 55% and specificity of 80.8%. 27 Previous breath studies have largely relied upon the combination of changes in several VOCs to generate a risk prediction model. 9, 10, 21 Only few studies have demonstrated the association of a single VOC biomarker with a disease state; hydrogen cyanide with Pseudomonas aeruginosa infection, and pentane with inflammatory bowel disease. 28, 29 On the contrary, our investigations have the limitations of a single-center study in both clinical and analytical aspects. A larger multicenter study that is powered to provide a definitive answer for test accuracy is currently being planned. The performance of breath test requires investigations in early stages of CRCa and specific adenoma subtypes, and specific investigation in asymptomatic patients to evaluate the role of breath propanal as a screening investigation for CRCa. Thirty-four percent of patients in the CRCa group received neoadjuvant therapy; studying of the effect of neoadjuvant therapy upon breath analysis, along with a correlation between propanal levels and response to neoadjuvant therapies are important areas for additional investigation. Although we have shown repeatability of experimental measurements over a short time period, 20 the reproducibility of the results using mass-spectrometry instruments in different laboratories or with the same instruments in a central laboratory over a long period of time should be carefully examined before the clinical uptake of any proposed breath test. Due to insufficient statistical power, we did not evaluate the effect of tumor stage, histology, and location upon propanal level. Patients with active colitis or diverticulitis were excluded from the present study; however, like other authors, we have previously shown using the same analytical platform that propanal is not significantly different between patients with inflammatory bowel disease compared with healthy controls. [29] [30] [31] The mechanism of propanal production and aldehyde dysregulation remains an important area for future work that can improve the understanding of confounding factors and improve the control measures on administering the test.
Our discovery and validation experiments were conducted in symptomatic colorectal patients with CRCa, benign disease, or endoscopically normal colon. We had an excellent recruitment rate indicating test acceptability to patients with colorectal symptoms because of the nature and simplicity of exhaled breath testing. While planning a definitive diagnostic accuracy study, it is important to study the proposed location of an exhaled breath test for CRCa. We envisage the use of such test as a triage investigation to direct patients to have endoscopy. If the test has an acceptable sensitivity and specificity and patient acceptability, it may prove cost-effective and improve the diagnostic pathway in patients with colorectal symptoms, an impact that requires several studies to investigate, yet an important vision to outline at an early stage.
